MNG
TEVA icon

Manning & Napier Group’s Teva Pharmaceuticals TEVA Stock Holding History

Manning & Napier Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,191
Closed -$247K – 344
2018
Q2 		$247K Buy
+10,191
New +$208K ﹤0.01% 317

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Manning & Napier Group's TEVA Position: Q3 2018 in Review

Manning & Napier Group sold out of Teva Pharmaceuticals (TEVA) in Q3 2018, closing a stake of 10,191 shares — an estimated $247K sold.

Manning & Napier Group first reported a position in TEVA in Q2 2018 and held it in 1 quarter. The position peaked at $247K in Q2 2018. 556 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

  • Manning & Napier Group reported no remaining Teva Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Manning & Napier Group sold 10,191 Teva Pharmaceuticals shares in Q3 2018, an estimated $247K.
  • Manning & Napier Group first reported a position in Teva Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Manning & Napier Group's Teva Pharmaceuticals position peaked at $247K in Q2 2018.
  • 556 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on Manning & Napier Group's 13F filing for Q3 2018, filed 10 Oct 2018.